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Fatal herpes simplex virus 
hepatitis complicating 
chemotherapy with weekly 
docetaxel
We report a 50-year-old female patient who was diagnosed with
metastatic breast cancer 3.5 years ago. Her most recent treatment
for liver and lymph node metastases was docetaxel given on a
weekly schedule. Standard prophylaxis with dexamethasone prior
to each docetaxel infusion was given. After a 6-week course, a
computed tomography (CT) scan revealed partial remission of
the liver and lymph node metastases. Therapy was resumed after
a 3-week interval. The patient was hospitalized with a decreased
performance status (suffering from nausea and vomiting) 72 h
after administration of dexamethasone and docetaxel. Laboratory
analysis showed an anicteric hepatitis with pronounced elevation
of serum aminotransferases (aspartate aminotransferase 3283 U/l,
alanine aminotransferase 1987 U/l), but normal bilirubin and
leukopenia (0.6 × 109/l). No mucocutaneous lesions, typically
suggestive of herpes simplex virus (HSV) infection, were detect-
able. Despite intensive supportive care the patient died of
fulminant liver failure on the fifth day after chemotherapy. A
liver biopsy taken immediately post mortem disclosed the strik-
ing pathological finding of non-inflammatory liver necrosis with
classical features of internuclear eosinophilic inclusion bodies,
and a homogeneous immunohistochemical staining for HSV.
Herpes simplex virus-induced hepatitis is a rare infection in
immunocompetent adults, but patients with impaired cellular
immunity may be at risk. HSV hepatitis often presents as a
fulminant disease that is usually fatal (>80%). Clinical features
include fever, anorexia with nausea and/or vomiting, abdominal
pain, leukopenia, coagulopathy and elevation of serum amino-
transferases without jaundice. Characteristic oral and/or genital
lesions occur in only 30% of cases [1, 2]. To our knowledge, there
have been no previous reports of fatal HSV hepatitis complicat-
ing chemotherapy with weekly low-dose docetaxel treatment in
combination with dexamethasone. However, infection may go
unnoticed, even post mortem, due to rapid autolysis of the liver
tissue.
As potentially effective treatment for HSV infection is avail-
able (acyclovir), we suggest transjugular liver biopsy as a safe
diagnostic procedure in cases of rapid performance status
deterioration and pronounced liver enzyme elevation in patients
undergoing chemotherapy. Serum HSV DNA detection might be
of false positive significance due to irrelevant former exposure to
the virus [3].
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